Full-Time
Specialty chemicals provider for coatings, pharma
No salary listed
Kenedy, TX, USA
In Person
Ashland is a diversified specialty chemicals company that originated as an oil refinery in 1924 and gradually shifted into chemicals, construction, and coal before fully reinventing itself as a pure-play specialty chemicals provider. Its products serve the personal care, pharmaceutical, and coatings markets. The company operates by developing and supplying chemical ingredients used in formulations across these industries, rather than delivering consumer finished goods. Compared with competitors, Ashland focuses on specialty chemical ingredients with an emphasis on performance materials and advanced additives, supported by a history of strategic acquisitions and spin-offs that steered it away from refining into differentiated chemical solutions. The company’s goal is to grow as a leading supplier of high-value, specialty ingredients by applying chemistry to improve the performance and quality of its customers’ products.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Covington, Kentucky
Founded
1924
Help us improve and share your feedback! Did you find this helpful?
People at Ashland who can refer or advise you
Health Insurance
Paid Vacation
Paid Holidays
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Wellness Program
In-Cosmetics Global 2026: Ashland to debut "glocalized" innovations and bio-based ingredients. Key takeaways. * Ashland unveils new technology platforms targeting hair care and formulation performance at In-Cosmetics Global in Paris. * Innovations emphasize sustainability, including reduced water use, biodegradable polymers, and bio-based ingredients. * New ingredients focus on multifunctionality, from antimicrobial boosting to anti-aging and lightweight conditioning. Ashland is set to reveal platform innovations and novel ingredients at In-cosmetics Global 2026 in Paris, France, this week (April 14-16). The additives and specialty ingredients company's "glocalized" launches focus on solutions tailored for region-specific culture, country, and regulatory needs. The launches include two technology platform expansions with applications in hair care and viscosity control, and four ingredient innovations. "Ashland high-performance innovations derived from our New Technology Platforms will help our customers elevate their end-products and create one-of-a-kind targeted, market-ready solutions," says Galder Cristobal, senior director of Personal Care Innovation at Ashland. Hair and viscosity. Part of the Ashland Super Wetters Technology Platform, the easy-hance wetting agent is a biologically-sourced superwetting agent for textured hair. It aids in detangling, alignment, and general efficacy in rinse-off and leave-on products by facilitating faster and more efficient wetting. A key sustainability benefit of the ingredient is reduced water usage and shortened wash routines without sacrificing strand hydration, curl definition, and tameability. Ashland states that the ingredient reduces formulator reliance on heavy oils and silicones. The company will also launch its first commercial innovation from the Ashland Multi-functional Starch Platform, Stabileze S polymer. The starch-based, versatile polymer is said to embolden stability in formulations and an appealing sensorial experience through its viscosity control, emulsion stabilization, and formulation suspension benefits at low use levels. Ingredient innovations. Effisin EM Natural Multifunctional is a fully biologically sourced, water-soluble antimicrobial booster aligned with use in various segment formulations. It supplies broad pH compatibility and low use levels, enabling formulators to streamline preservation systems while maintaining formulation simplicity and low costs. The next ingredient featured at In-cosmetics Global 2026 is Eternight. It enhances nighttime mitobiology and is built on the three R longevity approach - rest, restore, and reverse. It is formulated with an AI-guided iris pallida root extract. Ashland states that clinical testing on the ingredient has demonstrated visible improvements to eight signs of aging, leaving skin appearing more radiant and youthful. After one month, AI facial scan assessments indicated that skin appeared up to four years younger. From Ashland's Responsible Solvers program, N-hance CCG75 cationic guar is a biodegradable, nature-derived polymer made for clear, surfactant-based formulations with medium-to-high conditioning performance properties. The ingredient is touted to maintain optical clarity while providing effective wet and dry conditioning and avoiding heavy buildup. This enables its use in lightweight hair care solutions and cleansers across sulfated and non-sulfated systems. "Through this program, Ashland is increasing the volume of guar harvested annually through educational programs and scientific solutions for sustainable farming while respecting the sourcing relationships and local cultures of small village farmers in Rajasthan, India," says the company. So far, the Responsible Solvers program has helped farmers lower production costs while improving their crop yield by up to 20%, bolstering the farmers' income and strengthening small local economies. Finally, added to the Phyteq portfolio, the Phyteq Raspberry Plus Multifunctional is an antioxidant liquid-blend that is said to be as efficacious as its predecessor, Phyteq Raspberry. However, this iteration possesses wider antimicrobial performance and carries more diverse formulation applications.
Ashland CFO to discuss current market environment at the Gabelli Funds' 17th Annual Specialty Chemicals Symposium. Fireside chat to be webcast live during the symposium. March 17, 2026 17:01 ET | Source: Ashland, Inc. WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) - William C. Whitaker, senior vice president and chief financial officer, Ashland (NYSE: ASH), will participate in a fireside chat at the Gabelli Funds' 17th Annual Specialty Chemicals Symposium on Thursday, March 19, 2026, at 1:30 p.m. ET. Whitaker will also host one-on-one meetings with institutional investors throughout the day. The symposium will feature discussions with leading companies and organizations across the specialty chemicals ecosystem, with an emphasis on industry dynamics, current trends, business fundamentals, and specialty chemicals investing. Investment professionals and individual investors interested in the specialty chemicals sector can register to listen to the live webcast at: About Ashland Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,900 passionate, tenacious solvers thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. FOR FURTHER INFORMATION: | Investor Relations: | Media Relations: | | Sandy Klugman | Carolmarie C. Brown | | +1 (302) 594-7777 | +1 (302) 995-3158 | | [email protected] | [email protected] |
Ashland Inc reported a fiscal first-quarter loss of $12 million, or 26 cents per share. Adjusted earnings came in at 26 cents per share, beating Wall Street expectations of 23 cents per share. The Wilmington, Delaware-based chemical company posted revenue of $386 million for the period, falling short of analyst forecasts of $408.3 million. The company expects full-year revenue between $1.84 billion and $1.91 billion. Ashland shares have risen nearly 5% since the start of the year but declined 3% over the past 12 months, trading at $61.56 on Monday.
Ashland reported first quarter fiscal 2026 sales of $386 million, down 5% year-over-year. The previously announced Avoca divestiture reduced sales by approximately $10 million; excluding this, sales declined 3%. The company posted a net loss of $12 million, or $0.26 per diluted share. Adjusted EBITDA totalled $58 million, down 5% from the prior year, with the Avoca divestiture contributing a $1 million decline. The Calvert City outage negatively impacted Adjusted EBITDA by approximately $10 million. Cash flows from operating activities reached $125 million, whilst Ongoing Free Cash Flow was $26 million. Ashland narrowed its full-year fiscal 2026 Adjusted EBITDA guidance to $400–$420 million, reflecting approximately $11 million of temporary impacts from the Calvert City startup delay and recent weather-related disruptions isolated to the second quarter.
Ashland adds high purity sucrose and parenteral applications to injectables portfolio, and highlights expanded low nitrite pharmaceutical excipients. CPhI Frankfurt and AAPS harmsci 360 review. Ashland showed multiple new and optimized pharmaceutical product offerings during CPHI Frankfurt and AAPS PharmSci 360. To respond to global customer needs, Ashland has introduced vialose(TM) sucrose, a high purity sucrose for parenteral formulations that protects and shields biological molecules in injectables. Vialose(TM) sucrose meets the lowest levels of endotoxins (<0.2 g/EU) and meets NF, EP, JP, BP and ChP monograph specifications. The addition of sucrose expands Ashland's portfolio of vialose(TM) high purity sugar excipients, which already includes trehalose dihydrate. These sugars are used in life saving medicines as lyoprotectants and for protein stabilization in monoclonal antibodies, antibody-drug conjugates (ADCs), vaccines, peptides and stem cells. This growing family of stabilizing sugars demonstrates Ashland's commitment to delivering high-quality ingredients for the injectable and vaccine markets. Looking ahead, Ashland is planning to bring vialose(TM) mannitol to market later in 2026, further broadening its offerings to meet diverse formulation needs. "We're excited to introduce vialose(TM) sucrose, our latest premier performance sugar for use in biologic medicines," said Shawn Branning, global business line owner - cyclodextrins and biopharma, Ashland. "Our high purity sucrose, used to stabilize proteins and act as a lyoprotectant, is tested to meet the lowest levels of endotoxins and ChP monograph specifications, making it an ideal choice for use in biologic formulations." Within the pharmaceuticals portfolio, Ashland offers an array of oral solid dose (OSD) solutions, parenteral excipients (injectables) and film coating system solutions that improve, protect, and moderate the delivery of medicines. These ingredients include both time-controlled and immediate-release agents, as well as high-purity and low-nitrite offerings. To reduce the risk of nitrosamines in drug products, Ashland offers excipients with competitively low nitrite levels to help mitigate associated risks and ensure patient safety. By providing detailed nitrite specifications, Ashland empowers customers to make informed decisions and enhance their own quality control measures. Plasdone(TM) low nitrite povidone and polyplasdone(TM) LN crospovidone grades offer a nitrite specification of <100ppb with results reported on every CoA, setting a new benchmark for transparency and regulatory compliance. Benecel(TM) xr/xrf low nitrite hypromellose offers a nitrite specification of <200ppb with results reported on every CoA. Ashland solvers are known as the expert's expert, helping customers solve tomorrow's challenges today. The company has R&D centers of excellence in every region around the globe. Their iSolve(SM) digital portal puts information at users' fingertips. Ashland has regulatory experts that support customers across all regions and in-house manufacturing, backward integration, sourcing, and delivery in 93 countries and is responsibly solving for healthier lives, everywhere. "Our newly introduced excipients with signiffcantly reduced nitrite levels - including plasdone(TM) low nitrite povidone, polyplasdone(TM) LN crospovidone and benecel(TM) low nitrite hypromellose - help our customers mitigate nitrosamine formation in their final drug products. Providing high-quality materials that equip our stakeholders to make informed decisions, coupled with superior customer and technical service continues to position Ashland as an industry leader in the pharmaceutical space," Caroline Cooreman, director strategy and business development, OSD, Ashland. To learn more or to request a meeting at the tradeshows, visit the CPHI overview or the AAPS overview. For more information on vialose(TM) sucrose, viatel(TM) bioresorbable polymers, plasdone(TM) low nitrite povidone and polyplasdone(TM) LN crospovidone grades contact your local Ashland solver. or continue reading here